Aktuellt
SENASTE
Redeye provides a first comment on today’s news regarding the strategic licensing deal with Selecta Bioscience. The partnership, which includes an upfront and early milestone payments of USD 6m, additional milestone payments of up to USD 598m and double-digit royalties on sales, will give Genovis the opportunity to expand in the field of gene therapy and autoimmune diseases. We will review the case and return with a more extended research note, where we will increase our fair value range.
LÄS MER
